PubRank
Search
About
XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC)
Clinical Trial ID NCT00417079
PubWeight™ 35.58
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT00417079
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Lancet
2010
19.74
2
Novel therapies for metastatic castrate-resistant prostate cancer.
J Natl Cancer Inst
2011
1.98
3
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.
Ann Oncol
2013
1.76
4
Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.
Ann Oncol
2014
1.72
5
Tubulin-interactive natural products as anticancer agents.
J Nat Prod
2009
1.59
6
Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.
Clin Cancer Res
2015
1.13
7
Haphazard reporting of deaths in clinical trials: a review of cases of ClinicalTrials.gov records and matched publications-a cross-sectional study.
BMJ Open
2013
1.12
8
Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors.
Cancer Chemother Pharmacol
2013
1.05
9
Update on options for treatment of metastatic castration-resistant prostate cancer.
Onco Targets Ther
2010
1.00
10
[Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: the TROPIC study in France].
Bull Cancer
2012
0.87
11
Preclinical profile of cabazitaxel.
Drug Des Devel Ther
2014
0.85
12
The European Medicines Agency review of cabazitaxel (Jevtana®) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use.
Oncologist
2012
0.81
13
Emerging targeted therapies for castration-resistant prostate cancer.
Front Endocrinol (Lausanne)
2012
0.81
14
Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies.
Ther Clin Risk Manag
2014
0.80
15
Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours.
BMC Cancer
2013
0.76
16
Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies.
Anticancer Drugs
2015
0.75
Next 100